TEVA logo

TEVA Cash and cash equivalents

annual cash & cash equivalents:

$3.30B+$74.00M(+2.29%)
December 31, 2024

Summary

  • As of today (May 29, 2025), TEVA annual cash & cash equivalents is $3.30 billion, with the most recent change of +$74.00 million (+2.29%) on December 31, 2024.
  • During the last 3 years, TEVA annual cash & cash equivalents has risen by +$1.14 billion (+52.42%).
  • TEVA annual cash & cash equivalents is now -52.49% below its all-time high of $6.95 billion, reached on December 31, 2015.

Performance

TEVA Cash and cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

quarterly cash & cash equivalents:

$1.70B-$1.60B(-48.58%)
March 31, 2025

Summary

  • As of today (May 29, 2025), TEVA quarterly cash & cash equivalents is $1.70 billion, with the most recent change of -$1.60 billion (-48.58%) on March 31, 2025.
  • Over the past year, TEVA quarterly cash & cash equivalents has dropped by -$1.29 billion (-43.26%).
  • TEVA quarterly cash & cash equivalents is now -75.70% below its all-time high of $6.98 billion, reached on June 30, 2016.

Performance

TEVA quarterly cash & cash equivalents Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherTEVAbalance sheet metrics

Cash and cash equivalents Formula

Cash & Cash Equivalents = Cash + Short-Term Investments

TEVA Cash and cash equivalents Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+2.3%-43.3%
3 y3 years+52.4%-22.0%
5 y5 years+67.1%-5.9%

TEVA Cash and cash equivalents Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+52.4%-48.9%at low
5 y5-yearat high+67.1%-48.9%at low
alltimeall time-52.5%>+9999.0%-75.7%>+9999.0%

TEVA Cash and cash equivalents History

DateAnnualQuarterly
Mar 2025
-
$1.70B(-48.6%)
Dec 2024
$3.30B(+2.3%)
$3.30B(-0.6%)
Sep 2024
-
$3.32B(+47.0%)
Jun 2024
-
$2.26B(-24.5%)
Mar 2024
-
$2.99B(-7.3%)
Dec 2023
$3.23B(+15.2%)
$3.23B(+43.4%)
Sep 2023
-
$2.25B(-15.7%)
Jun 2023
-
$2.67B(+24.5%)
Mar 2023
-
$2.14B(-23.5%)
Dec 2022
$2.80B(+29.4%)
$2.80B(+25.9%)
Sep 2022
-
$2.23B(+8.1%)
Jun 2022
-
$2.06B(-5.4%)
Mar 2022
-
$2.17B(+0.5%)
Dec 2021
$2.17B(-0.6%)
$2.17B(+5.9%)
Sep 2021
-
$2.04B(-16.1%)
Jun 2021
-
$2.44B(+39.8%)
Mar 2021
-
$1.74B(-19.9%)
Dec 2020
$2.18B(+10.2%)
$2.18B(+19.2%)
Sep 2020
-
$1.83B(-23.9%)
Jun 2020
-
$2.40B(+33.1%)
Mar 2020
-
$1.80B(-8.7%)
Dec 2019
$1.98B(+10.8%)
$1.98B(+59.1%)
Sep 2019
-
$1.24B(-42.7%)
Jun 2019
-
$2.17B(+9.7%)
Mar 2019
-
$1.97B(+10.7%)
Dec 2018
$1.78B(+85.0%)
$1.78B(-5.0%)
Sep 2018
-
$1.88B(+0.8%)
Jun 2018
-
$1.86B(+31.2%)
Mar 2018
-
$1.42B(+47.2%)
Dec 2017
$963.00M(-2.5%)
$963.00M(+41.6%)
Sep 2017
-
$680.00M(+13.5%)
Jun 2017
-
$599.00M(-33.4%)
Mar 2017
-
$900.00M(-8.9%)
Dec 2016
$988.00M(-85.8%)
$988.00M(-36.5%)
Sep 2016
-
$1.56B(-77.7%)
Jun 2016
-
$6.98B(+17.1%)
Mar 2016
-
$5.96B(-14.1%)
Dec 2015
$6.95B(+212.0%)
$6.95B(+648.5%)
Sep 2015
-
$928.00M(-13.1%)
Jun 2015
-
$1.07B(-68.6%)
Mar 2015
-
$3.40B(+52.6%)
Dec 2014
$2.23B(+114.5%)
$2.23B(+51.1%)
Sep 2014
-
$1.47B(+55.2%)
Jun 2014
-
$949.00M(+5.3%)
Mar 2014
-
$901.00M(-13.2%)
Dec 2013
$1.04B(-63.9%)
$1.04B(-9.6%)
Sep 2013
-
$1.15B(-7.8%)
Jun 2013
-
$1.25B(-10.7%)
Mar 2013
-
$1.39B(-51.6%)
Dec 2012
$2.88B(+162.7%)
$2.88B(+101.0%)
Sep 2012
-
$1.43B(+20.5%)
Jun 2012
-
$1.19B(+11.9%)
Mar 2012
-
$1.06B(-3.1%)
Dec 2011
$1.10B(-12.2%)
$1.10B(+1.0%)
Sep 2011
-
$1.08B(-4.7%)
Jun 2011
-
$1.14B(+58.0%)
Mar 2011
-
$721.00M(-42.2%)
Dec 2010
$1.25B
$1.25B(+33.5%)
Sep 2010
-
$935.00M(-80.7%)
Jun 2010
-
$4.85B(+106.0%)
DateAnnualQuarterly
Mar 2010
-
$2.36B(+18.1%)
Dec 2009
$2.00B(+7.6%)
$2.00B(+24.8%)
Sep 2009
-
$1.60B(-9.3%)
Jun 2009
-
$1.76B(-25.1%)
Mar 2009
-
$2.35B(+26.8%)
Dec 2008
$1.85B(+24.6%)
$1.85B(-35.0%)
Sep 2008
-
$2.85B(+14.9%)
Jun 2008
-
$2.48B(-1.0%)
Mar 2008
-
$2.51B(+68.6%)
Dec 2007
$1.49B(+11.7%)
$1.49B(-1.3%)
Sep 2007
-
$1.51B(-6.8%)
Jun 2007
-
$1.62B(+37.6%)
Mar 2007
-
$1.18B(-11.7%)
Dec 2006
$1.33B(+4.4%)
$1.33B(+59.8%)
Sep 2006
-
$833.50M(-3.4%)
Jun 2006
-
$863.10M(-10.9%)
Mar 2006
-
$968.30M(-24.1%)
Dec 2005
$1.28B(+62.8%)
$1.28B(+81.5%)
Sep 2005
-
$703.10M(-15.7%)
Jun 2005
-
$834.30M(+18.9%)
Mar 2005
-
$701.60M(-10.5%)
Dec 2004
$784.00M(-25.8%)
$784.00M(-14.6%)
Sep 2004
-
$918.10M(+29.0%)
Jun 2004
-
$711.70M(+0.2%)
Mar 2004
-
$710.00M(-32.8%)
Dec 2003
$1.06B(+30.5%)
$1.06B(+32.1%)
Sep 2003
-
$800.10M(-9.0%)
Jun 2003
-
$879.30M(-5.4%)
Mar 2003
-
$929.40M(+14.8%)
Dec 2002
$809.90M(+5.3%)
$809.90M(+117.8%)
Sep 2002
-
$371.80M(-35.5%)
Jun 2002
-
$576.30M(-11.9%)
Mar 2002
-
$653.80M(-15.0%)
Dec 2001
$768.92M(+82.8%)
$768.92M(-4.3%)
Sep 2001
-
$803.30M(+139.0%)
Jun 2001
-
$336.09M(-4.8%)
Mar 2001
-
$353.06M(-16.1%)
Dec 2000
$420.63M(+445.0%)
$420.63M(+350.3%)
Jun 2000
-
$93.41M(-13.7%)
Mar 2000
-
$108.25M(+40.3%)
Dec 1999
$77.18M(+63.9%)
$77.18M(-35.9%)
Sep 1999
-
$120.40M(+115.4%)
Jun 1999
-
$55.90M(-19.9%)
Mar 1999
-
$69.80M(+48.2%)
Dec 1998
$47.10M(-7.5%)
$47.10M(-15.6%)
Sep 1998
-
$55.80M(-41.4%)
Jun 1998
-
$95.30M(+56.5%)
Mar 1998
-
$60.90M(+19.6%)
Dec 1997
$50.90M(-16.8%)
$50.90M(-16.8%)
Dec 1996
$61.20M(-5.7%)
$61.20M(-5.7%)
Dec 1995
$64.90M(+53.1%)
$64.90M(+53.1%)
Dec 1994
$42.40M(+6.3%)
$42.40M(+6.3%)
Dec 1993
$39.90M(+189.1%)
$39.90M(+189.1%)
Dec 1992
$13.80M(+74.7%)
$13.80M(+74.7%)
Dec 1991
$7.90M(-48.7%)
$7.90M(-48.7%)
Dec 1990
$15.40M(+234.8%)
$15.40M(+234.8%)
Dec 1989
$4.60M(-64.9%)
$4.60M(-64.9%)
Dec 1988
$13.10M(-17.6%)
$13.10M(-17.6%)
Mar 1987
$15.90M(-29.0%)
$15.90M(-29.0%)
Mar 1986
$22.40M
$22.40M

FAQ

  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?
  • What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?
  • What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents?
  • What is the all time high quarterly cash & cash equivalents for Teva Pharmaceutical Industries Limited?
  • What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents year-on-year change?

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents?

The current annual cash & cash equivalents of TEVA is $3.30B

What is the all time high annual cash & cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high annual cash & cash equivalents is $6.95B

What is Teva Pharmaceutical Industries Limited annual cash & cash equivalents year-on-year change?

Over the past year, TEVA annual cash & cash equivalents has changed by +$74.00M (+2.29%)

What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents?

The current quarterly cash & cash equivalents of TEVA is $1.70B

What is the all time high quarterly cash & cash equivalents for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited all-time high quarterly cash & cash equivalents is $6.98B

What is Teva Pharmaceutical Industries Limited quarterly cash & cash equivalents year-on-year change?

Over the past year, TEVA quarterly cash & cash equivalents has changed by -$1.29B (-43.26%)
On this page